Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Vincerx Pharma, Inc. (VINC : OTC)

• Company Description    Vincerx Pharma Inc. is a biopharmaceutical company. It focuses on unmet medical needs of patients with cancer through paradigm-shifting therapeutics. Vincerx Pharma Inc. is based in PALO ALTO, Calif. Number of Employees: 13

• Price / Volume Information    Yesterday's Closing Price: $0.05 Daily Weekly Monthly 20 Day Moving Average: 129,523 shares Shares Outstanding: 5.23 (millions) Market Capitalization: $0.24 (millions) Beta: 1.72 52 Week High: $2.00 52 Week Low: $0.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -15.56% -19.80% 12 Week -32.54% -41.25% Year To Date -99.13% -99.19%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1825 S. GRANT STREET - SAN MATEO,CA 94402 USA ph: 650-800-6676 fax: - None http://www.vincerx.com

• General Corporate Information    Officers Raquel E. Izumi - Chief Executive Officer and Director Ahmed M. Hamdy - Chairman of the Board Kevin Haas - Chief Financial Officer Laura I. Bushnell - Director Brian J. Druker - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 92731L304 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/25 Next Expected EPS Date: 08/14/25 Share - Related Items Shares Outstanding: 5.23 Most Recent Split Date: 1.00 (0.05:1) Beta: 1.72 Market Capitalization: $0.24 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/14/25

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.12 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: 86.62% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - -284.97 12/31/24 - -373.17 ROA 06/30/25 - - 03/31/25 - -170.10 12/31/24 - -179.04 Current Ratio 06/30/25 - - 03/31/25 - 1.79 12/31/24 - 1.21 Quick Ratio 06/30/25 - - 03/31/25 - 1.79 12/31/24 - 1.21 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Book Value 06/30/25 - - 03/31/25 - 0.39 12/31/24 - 1.22 Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - - Debt-to-Equity 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00 Debt-to-Capital 06/30/25 - - 03/31/25 - 0.00 12/31/24 - 0.00

Powered by Zacks Investment Research ©